Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Sickle Cell Anemia Clinical Trial

Official title:

A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02961218
• Other study ID #: CACZ885X2206
• Status: Completed
• Phase: Phase 2
• Start date: April 5, 2017
• Est. completion date: April 27, 2020

Study information

• Verified date: October 2021
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study assesses the efficacy, safety and tolerability of ACZ885 (canakinumab) in pediatric and young adult patients with sickle cell anemia (SCA).

Description:

This was an ambulatory-based 24-week study followed by an additional 24-week open label phase. It was a subject- and investigator-blinded, randomized, placebo-controlled, parallel group, non-confirmatory study to assess the clinical efficacy of ACZ885 administered s.c. in six injections given 28 days apart (in each phase of the study).

Pediatric and young adult subjects diagnosed with sickle cell anemia (SCA) were planned to be randomized to either ACZ885 treatment or placebo treatment in a 1:1 ratio,.

For each subject, there was a maximum 28-day screening period that included recording of daily pain frequency and intensity by e-diary for at least 1 week. Subjects who met the eligibility criteria at screening underwent evaluation of baseline clinical and biomarker assessments prior to first dose administration.

On Day 1, monthly s.c. dosing with ACZ885 started at 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects. Subjects in the placebo treatment arm were injected with placebo in a like manner. All subjects returned to the study centers for safety checks on a monthly basis when they received treatment with either ACZ885 or placebo.

The final blinded dosing was given on Week 20, followed by blinded clinical assessments at Week 24. Subjects from both study arms were then offered optional, open label monthly dosing of ACZ885 for an additional 24 weeks (Weeks 24-48) with clinical outcome assessment.

Subjects returned for the end of study (EOS) visit at Week 56. For subjects who chose not to participate in the optional, open label portion of the study, or for those stopping treatment early for any other reason, an EOS visit occurred approximately 8 weeks after last dose received.

After enrollment of 49 subjects, Novartis decided to terminate the study early due to strategic reasons not related to safety and decided that no additional enrollment was needed in order to interpret the study objectives.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: April 27, 2020
• Est. primary completion date: June 27, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 20 Years

Eligibility

Inclusion Criteria:

• Male and female subjects ages 8-20 years of age (both inclusive) diagnosed with sickle cell anemia (HbSS) or sickle beta0 thalassemia (documented by family studies, or analysis of either hemoglobin or DNA).

• Patient's written informed consent from those =18 years of age must be obtained before any assessment is performed. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients < 18 years of age.

• Detectable baseline of background or episodic pain measured by daily e-diary over 1 to 2 weeks during screening period as defined below: Average daily pain score = 1 cm without analgesic use over a period of at least 7 days and/or, At least one episode of pain requiring analgesic use during a period of up to 14 days.

• History of =2 vaso-occlusive pain episodes in the past year, as defined as pain with no other, non-sickle cell identifiable cause that requires analgesia and interferes with the patient's normal daily routine.

Exclusion Criteria:

• History of known hypersensitivity to canakinumab.

• Ongoing or treatment with the past 3 months with red blood cell transfusion therapy, or have evidence of iron overload requiring chelation therapy.

• Transcranial Doppler ultrasound in the past year or at screening in patients with an accessible transtemporal window, demonstrating velocity in middle or anterior cerebral or internal carotid artery =200 cm/sec.

• Administration of any other blood products within 3 weeks of screening visit.

Other protocol-defined inclusion/exclusion criteria may apply.

Related Conditions & MeSH terms

• Anemia
• Anemia, Sickle Cell
• Sickle Cell Anemia

Intervention

Drug:
• ACZ885
Monthly doses of 4 mg/kg for subjects weighing =40 kg and 300 mg for all other subjects
• Placebo
Monthly doses of placebo to match the administered dose of canakinumab s.c.

Locations

Country	Name	City	State
Canada	Novartis Investigative Site	Toronto	Ontario
Germany	Novartis Investigative Site	Hamburg
Israel	Novartis Investigative Site	Afula
South Africa	Novartis Investigative Site	Johannesburg	Guateng
Turkey	Novartis Investigative Site	Adana
Turkey	Novartis Investigative Site	Ankara
Turkey	Novartis Investigative Site	Mersin
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Wolverhampton	Staffordshire
United States	Novartis Investigative Site	Atlanta	Georgia
United States	Novartis Investigative Site	Augusta	Georgia
United States	Novartis Investigative Site	Greenville	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Israel,  South Africa,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline of 4- Week Average Daily Pain Measured by Visual Analog Score (VAS) Over the Period of Week 8 to 12	Visual analog scale (VAS) was used to record severity. Pediatric and young adult participants rated their daily sickle cell associated pain intensity once each day in the evening using an 11-point numerical rating scale from 0 to 10 with higher ratings associated with more intense pain (0 = no pain, 10 = worst pain). For each subject, there was a maximum 28-day screening period that included recording of daily pain intensity by e-diary for at least 1 week. The average daily pain results in the screening period were used to derive the baseline value. The average over week 8 to 12 was calculated and the change from baseline in the average daily pain VAS was analyzed using a Bayesian model for repeated measures.	Baseline (upto 28 days prior to start of treatment), Week 8 to 12
Secondary	Change From Baseline of Average Daily Pain VAS Over 4 Weeks Intervals up to Week 24	Visual analog scale (VAS) was used to record severity. Pediatric and young adult participants rated their daily sickle cell associated pain intensity once each day in the evening using an 11-point numerical rating scale from 0 to 10 with higher ratings associated with more intense pain (0 = no pain, 10 = worst pain). The average of 4 weeks interval up to week 24 was calculated.	Baseline (upto 28 days prior to start of treatment), Week 0 to 4, Week 4 to 8, Week 8 to 12, Week 12 to 16, Week 16 to 20 and Week 20 to 24
Secondary	Change in the Concentration of High Sensitivity C-Reactive Protein (hsCRP) From Baseline to Week 12	hs-CRP is a biomarker that represents the inflammation process.	Baseline, Week 12
Secondary	Change in the Concentration of White Blood Cell (WBC) Count From Baseline to Week 12	WBC count was used as a laboratory marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Absolute Count of Neutrophils From Baseline to Week 12	Absolute count of neutrophils was measured as a laboratory marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Absolute Count of Blood Monocytes From Baseline to Week 12	Absolute count of blood monocytes was measured as a laboratory marker to determine the effect of the drug.	Baseline, Week 12
Secondary	Change in the Concentration of Hemoglobin From Baseline to Week 12	Hemoglobin was used as a hemolysis marker to determine the effect of the drug.	Baseline, Week 12
Secondary	Change in the Reticulocyte Count From Baseline to Week 12	Reticulocyte count was used as a hemolysis marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Bilirubin From Baseline to Week 12	Bilirubin was used as a hemolysis marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Lactate Dehydrogenase (LDH) From Baseline to Week 12	LDH was used as a hemolysis marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Haptoglobin From Baseline to Week 12	Haptoglobin was used as a hemolysis marker to determine the effect of the drug	Baseline, Week 12
Secondary	Change in the Concentration of Oxygen Percent Saturation (SAO2) From Baseline to Week 12	SAO2 was used as a hemolysis marker to determine the effect of the drug	Baseline, Week 12
Secondary	Number of Days Absent From School or Work Due to Pain as Recorded by E-diary	The number of SCA-related days absent from school or work were derived from eDiary records.	up to Week 24
Secondary	Number of Acute Blood Transfusions Per Patient by Study Period - Double-blind Period	The occurrence of acute blood transfusions was summarized as the proportion of subjects who received at least one acute blood transfusion and the event rate of acute blood transfusions per subject, by study period, group and reason of transfusion.	12 weeks
Secondary	Mean Serum Concentration After Repeated Dosing of ACZ885	PK samples were collected at Baseline, Week 4, 12, 20 and 24. Mean and standard deviation of the ACZ885 concentration was reported. Only those participants available at the specified time points were analyzed	Baseline, Week 4, 12, 20 and 24

External Links

•   A Plain Language Trial Summary is available on novartisclinicaltrials.com